Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer’s Mouse Phenotypes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Metabotropic glutamate receptor 5 (mGluR5) has been implicated in Alzheimer's disease (AD) pathology. We sought to understand whether mGluR5's role in AD requires glutamate signaling. We used a potent mGluR5 silent allosteric modulator (SAM, BMS-984923) to separate its well-known physiological role in glutamate signaling from a pathological role in mediating amyloid-β oligomer (Aβo) action. Binding of the SAM to mGluR5 does not change glutamate signaling but strongly reduces mGluR5 interaction with cellular prion protein (PrP C ) bound to Aβo. The SAM compound prevents Aβo-induced signal transduction in brain slices and in an AD transgenic mouse model, the APPswe/PS1ΔE9 strain. Critically, 4 weeks of SAM treatment rescues memory deficits and synaptic depletion in the APPswe/PS1ΔE9 transgenic mouse brain. Our data show that mGluR5's role in Aβo-dependent AD phenotypes is separate from its role in glutamate signaling and silent allosteric modulation of mGluR5 has promise as a disease-modifying AD intervention with a broad therapeutic window.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…memory dysfunction, all of which are key characteristics of the disease (Berman et al., 2008; Cleary et al., 2005; Hong et al., 2016; Lacor et al., 2007; Lambert et al., 1998; Laurén et al., 2009; Lesné et al., 2006; Li et al., 2009; Palop and Mucke, 2010; Shankar et al., 2008; Walsh et al., 2002).”
BackgroundRetractedThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“…memory dysfunction, all of which are key characteristics of the disease (Berman et al., 2008; Cleary et al., 2005; Hong et al., 2016; Lacor et al., 2007; Lambert et al., 1998; Laurén et al., 2009; Lesné et al., 2006; Li et al., 2009; Palop and Mucke, 2010; Shankar et al., 2008; Walsh et al., 2002).”
BackgroundComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 2×
“…mediator recruitment, and memory dysfunction, all of which are key characteristics of the disease (Berman et al., 2008; Cleary et al., 2005; Hong et al., 2016; Lacor et al., 2007; Lambert et al., 1998; Laurén et al., 2009; Lesné et al., 2006; Li et al., 2009; Palop and Mucke, 2010;…”
BackgroundTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 2×
“The SAM Rescues Tau Pathology in Triple-Transgenic Mice Pathological tau is a further characteristic of AD (reviewed in Ballatore et al., 2007), but it is not modeled in the APP/PS1 transgenic model.”
BackgroundAmyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 2×
“…memory dysfunction, all of which are key characteristics of the disease (Berman et al., 2008; Cleary et al., 2005; Hong et al., 2016; Lacor et al., 2007; Lambert et al., 1998; Laurén et al., 2009; Lesné et al., 2006; Li et al., 2009; Palop and Mucke, 2010; Shankar et al., 2008; Walsh et al., 2002).”
BackgroundJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 3×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript ameliorate behavioral deficits of aged APP/PS1 transgenic mice (Jankowsky et al., 2003, 2004), we assessed their behavior in multiple behavioral paradigms after 4 weeks of treatment with the SAM or vehicle.”
BackgroundMethod
Cited by
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies
Chen, Y., Fu, A. K. Y., & Ip, N. Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.006 · Cited by 258
Bukke, V. N., Archana, M., Villani, R., Romano, A. D., Wawrzyniak, A., Balawender, K., Orkisz, S., Beggiato, S., Serviddio, G., & Cassano, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207452 · Cited by 161
Spurrier, J., Nicholson, L., Fang, X. T., Stoner, A. J., Toyonaga, T., Holden, D., Siegert, T. R., Laird, W., Allnutt, M. A., Chiasseu, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi8593 · Cited by 114
Self-citationAlzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss
Salazar, S. V., Cox, T. O., Lee, S., Brody, A. H., Chyung, A. S., Haas, L. T., & Strittmatter, S. M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1873-18.2018 · Cited by 77
“Moreover, the transgenic AD mice exhibit elevated Pyk2 function, which is normalized by PrP C deletion, by mGluR5 deletion or inhibition, or by Fyn inhibition in parallel with rescue of synapses and memory (Kaufman et al., 2015; Haas and Strittmatter, 2016; Haas et al., 2016, 2017).”
BackgroundResultInfluentialSelf-citationAkyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
“The role of mGluR5 in AβO-dependent AD phenotypes was found to be different from its role in glutamate signaling [38].”
Li, S., Cai, Z., Zhang, W., Holden, D., Lin, S.-F., Finnema, S. J., Shirali, A., Ropchan, J., Carre, S., Mercier, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04357-w · Cited by 59
Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation
Woo, M. S., Ufer, F., Rothammer, N., Di Liberto, G., Binkle, L., Haferkamp, U., Sonner, J. K., Engler, J. B., Hornig, S., Bauer, S., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201290 · Cited by 56
Lee, S., Salazar, S. V., Cox, T. O., & Strittmatter, S. M. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.2983-18.2018 · Cited by 55
Self-citationMetabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease
Caraci, F., Nicoletti, F., & Copani, A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.12.001 · Cited by 37
Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice
Cox, T. O., Gunther, E. C., Brody, A. H., Chiasseu, M. T., Stoner, A., Smith, L. M., Haas, L. T., Hammersley, J., Rees, G., Dosanjh, B., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.730 · Cited by 33
Self-citation
Metadata
- Authors
- Haas, L. T., Salazar, S. V., Smith, L. M., Zhao, H. R., Cox, T. O., Herber, C. S., Degnan, A. P., Balakrishnan, A., Macor, J. E., Albright, C. F., & Strittmatter, S. M.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 20
- Issue
- 1
- Pages
- 76-88
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2730829886
- Cited by
- 118
- References
- 23
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.